Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
